Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
277.33
-1.84 (-0.66%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
October 25, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
October 25, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Expert Ratings for Alnylam Pharmaceuticals
October 16, 2023
Via
Benzinga
Analyst Expectations for Alnylam Pharmaceuticals's Future
September 29, 2023
Via
Benzinga
What 16 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
September 12, 2023
Via
Benzinga
Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
October 19, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
October 18, 2023
The company can begin a pivotal study of its treatment for cardiomyopathy.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
October 11, 2023
Via
Benzinga
CSX To Rally Around 27%? Here Are 10 Other Analyst Forecasts For Wednesday
October 11, 2023
Morgan Stanley cut Netflix, Inc. (NASDAQ: NFLX) price target from $450 to $430. Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating. Netflix shares rose 0.8% to $375.51 in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023
October 11, 2023
Via
Benzinga
Why Is Genetic Disease-Focused Alnylam Pharmaceuticals Stock Trading Lower Today?
October 09, 2023
The FDA has issued a Complete Response Letter (CRL) to Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) supplemental New Drug Application (sNDA) for patisiran for cardiomyopathy of transthyretin-
Via
Benzinga
Exposures
Product Safety
Alnylam Stock Crumbles After The FDA Unexpectedly Rejects Its Heart Drug
October 09, 2023
Shares skidded to their lowest point since September on the FDA's rejection.
Via
Investor's Business Daily
Exposures
Product Safety
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
October 09, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
2 Growth Stocks That Could Rocket Higher Before the End of 2023
October 08, 2023
Potential approvals of new medicines expected soon could push these stocks through the roof.
Via
The Motley Fool
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023
October 06, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
October 05, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
September 29, 2023
Via
Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
September 27, 2023
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY
Via
Benzinga
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects
September 14, 2023
On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran.
Via
Benzinga
Exposures
Product Safety
Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer
September 14, 2023
Its heart disease drug could gain approval, but FDA advisors don't expect it to take on Pfizer's leading drug.
Via
Investor's Business Daily
Exposures
Product Safety
Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease
September 14, 2023
On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran.
Via
Benzinga
Exposures
Product Safety
Nasdaq, S&P 500 Futures In Green As Traders Look Past Inflation Data; Analyst Singles Out Key Catalyst That Can Keep Year's Rally Going
September 14, 2023
US stocks could open Thursday's session higher, apparently in relief rally following the August inflation data.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
September 13, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
September 13, 2023
These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments.
Via
InvestorPlace
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
September 13, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
September 11, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 08, 2023
Via
Benzinga
Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public'
September 08, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norfolk Southern Corporation (NYSE: NSC) is the "cheapest I’ve seen in a very long time,
Via
Benzinga
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
September 07, 2023
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.